DNA

Ginkgo Bioworks Holdings Inc

Add to Watchlist

Advanced Chart

10.130

+0.37(3.791%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

10.4397

Open

9.970

VWAP

10.15

Vol

1.55M

Mkt Cap

562.54M

Low

9.780

Amount

15.75M

EV/EBITDA(TTM)

Total Shares

2.21B

45.62M

EV/OCF(TTM)

P/S(TTM)

2.26

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

40.91M

-27.21%

43.41M

-51.26%

44.20M

+0.81%

Estimates Revision

The market is revising Upward the revenue expectations for Ginkgo Bioworks Holdings, Inc. (DNA) for FY2025, with the revenue forecasts being adjusted by 3.26% over the past three months. During the same period, the stock price has changed by 38.01%.

Revenue Estimates for FY2025

Revise Upward

+3.26%

In Past 3 Month

Stock Price

Go Up

+38.01%

In Past 3 Month

5 Analyst Rating

-11.15% Downside

Wall Street analysts forecast DNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNA is 9.00 USD with a low forecast of 6.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

3 Sell

Moderate Sell

-11.15% Downside

Current: 10.130

Low

6.00

Averages

9.00

High

12.00

-11.15% Downside

Current: 10.130

Low

6.00

Averages

9.00

High

12.00

TD Cowen

Brendan Smith

Strong Buy

Maintains

$3 → $10

2024-09-20

Reason

TD Cowen

Brendan Smith

Price Target

$3 → $10

2024-09-20

Maintains

Strong Buy

Reason

BTIG

Mark Massaro

Strong Sell

Maintains

$0.2 → $7

2024-08-23

Reason

BTIG

Mark Massaro

Price Target

$0.2 → $7

2024-08-23

Maintains

Strong Sell

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Ginkgo Bioworks Holdings Inc (DNA.N) is -1.68, compared to its 5-year average forward P/E of -16.44. For a more detailed relative valuation and DCF analysis to assess Ginkgo Bioworks Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-16.44

Current PE

-1.68

Overvalued PE

14.04

Undervalued PE

-46.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-19.09

Current EV/EBITDA

-2.95

Overvalued EV/EBITDA

16.90

Undervalued EV/EBITDA

-55.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

13.64

Current PS

3.38

Overvalued PS

28.58

Undervalued PS

-1.30

Financials

Annual

Quarterly

FY2025Q1

YoY :

+27.34%

48.32M

Total Revenue

FY2025Q1

YoY :

-46.70%

-84.61M

Operating Profit

FY2025Q1

YoY :

-45.18%

-90.96M

Net Income after Tax

FY2025Q1

YoY :

-49.24%

-1.68

EPS - Diluted

FY2025Q1

YoY :

-38.37%

-59.14M

Free Cash Flow

FY2025Q1

YoY :

-0.90%

75.07

Gross Profit Margin - %

FY2025Q1

YoY :

-5.81%

-145.44

FCF Margin - %

FY2025Q1

YoY :

-56.95%

-188.25

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

5.4K

USD

3-6

Months

40.4K

USD

6-9

Months

34.2K

USD

0-12

Months

21.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

281.0K

Volume

6-9

Months

287.5K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

1.8M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

5.4K

USD

3-6

Months

40.4K

USD

6-9

Months

34.2K

USD

0-12

Months

21.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

DNA News & Events

Events Timeline

2025-07-07 (ET)

2025-07-07

12:02:07

Ginkgo Bioworks falls -10.2%

2025-06-30 (ET)

2025-06-30

12:00:38

Ginkgo Bioworks rises 17.0%

2025-06-11 (ET)

2025-06-11

09:47:22

Ginkgo Bioworks rises 5.4%

News

5.0

07-17PRnewswire

Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors

2.0

07-17NASDAQ.COM

Ginkgo Bioworks Holdings, Inc. (DNA) Outperforms Broader Market: What You Need to Know

2.0

07-11NASDAQ.COM

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Sinks As Market Gains: Here's Why